Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Kashiwa-shi
Clinical trial register · Japan

Clinical Trials in Kashiwa-shi, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AbbVie42 Amgen18 AstraZeneca8 Daiichi Sankyo8 Ono Pharmaceutical Co., Ltd.7
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Kashiwa-shi

137 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
AstraZeneca
Phase 3
950
Fukushima, Ginowan-shi, Hidaka-shi, Isehara-shi, Kashiwa-shi, Kawasaki-shi, Kobe, Kōtoku
2026-09-16
Recruiting
Incyte Corporation
Phase 3
426
Bunkyō City, Chūō, Fukuoka, Fukushima, Hirakata, Kagoshima, Kashiwa-shi, Kobe
2026-09-08
Recruiting
AstraZeneca
Phase 3
600
Asahikawa-shi, Kamakura-shi, Kashiwa-shi, Kobe, Komoro, Kumamoto, Kyoto, Miyazaki
2026-07-08
Recruiting
AbbVie
Phase 3
990
Kashiwa-shi, Matsuyama, Kobe, Kawasaki-shi, Osaka, Koto-ku
2026-05-22
Recruiting
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
NCT07488676Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
DrugXNW27011
Astellas Pharma Global Development, Inc.
Phase 1/2
150
Kashiwa-shi, Chuo-ku, Koto-ku
2026-05-04
Recruiting
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
NCT07403721Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Amgen
Phase 1
464
Nagoya, Kashiwa-shi, Chuo-ku, Koto-ku
2026-04-08
Recruiting
Incyte Corporation
Phase 3
700
Akashi-shi, Chiba, Chūōku, Fukuoka, Hidaka-shi, Kashiwa-shi, Kawasaki-shi, Kita-gun
2026-03-05
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1/2
428
Kashiwa-shi, Hirakata-shi, Chuo-ku, Koto-ku
2026-02-05
Recruiting
Bristol-Myers Squibb
Observational
150
Chiba, Kashiwa-shi, Sakura, Matsuyama, Chikushino-shi, Fukuoka, Asahikawa, Sapporo
2026-01-29
Recruiting
Daiichi Sankyo
Phase 1
60
Kashiwa-shi, Kobe, Kōtoku, Sakura-shi
2025-12-03
Recruiting
AbbVie
Phase 2
100
Nagoya, Kashiwa-shi, Fukuoka, Sapporo, Kyoto, Sendai, Okayama, Chuo-Ku
2025-12-01
Recruiting
AbbVie
Phase 1
285
Kashiwa-shi, Hidaka, Sunto-gun
2025-11-27
Recruiting
AbbVie
Phase 2
180
Kashiwa-shi, Sunto-gun, Bunkyo Ku, Chuo-Ku, Wakayama
2025-11-25
Recruiting
AbbVie
Phase 1
220
Kashiwa-shi, Hirakata-shi
2025-11-20
Recruiting
Daiichi Sankyo
Phase 3
686
Hidaka-shi, Hirakata-shi, Hirosaki-shi, Kashiwa-shi, Kawasaki-shi, Kitakyushu-shi, Kumamoto, Kurume-shi
2025-10-24
Recruiting
AbbVie
Observational
200
Nagakute, Nagoya, Hirosaki, Chiba, Kashiwa-shi, Sakura, Fukuoka, Hiroshima
2025-10-09
Recruiting
Genentech, Inc.
Phase 2
224
Kashiwa-shi, Fukuoka, Fukuyama-shi, Kanazawa, Takamatsu, Osaka, Saga, Fujidera-shi
2025-09-29
Recruiting
AbbVie
Phase 2
140
Nagoya, Kashiwa-shi, Fukuoka, Gifu, Yokohama, Sendai, Osaka, Sunto-gun
2025-09-02
Recruiting
AbbVie
Phase 1
135
Kashiwa-shi, Kumamoto, Mibu, Bunkyo-ku, Koto-ku
2025-08-07
Recruiting
AstraZeneca
Phase 3
800
Chūōku, Hidaka-shi, Isehara-shi, Kashiwa-shi, Kōtoku, Kurume-shi, Matsuyama, Minatoku
2025-08-01
Recruiting
Amgen
Phase 1
434
Nagoya, Kashiwa-shi, Chuo-ku
2025-07-31
Recruiting
AbbVie
Phase 3
120
Ōbu, Kashiwa-shi, Kurume-shi, Maebashi, Kobe, Kumamoto, Saga, Saitama-shi
2025-07-28
Recruiting
Yukinori Ozaki
Phase 2
24
Nagoya, Kashiwa-shi, Gifu, Hiroshima, Sapporo, Akashi-shi, Okayama, Osaka
2025-06-24
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
DrugsCetuximab·Docetaxel
Revolution Medicines, Inc.
Phase 3
590
Nagoya, Toyoake-shi, Kashiwa-shi, Matsuyama, Sapporo, Akashi, Kanazawa, Sagamihara
2025-05-06
Recruiting
AbbVie
Phase 2
390
Nagoya, Kashiwa-shi, Kawasaki-shi, Sendai, Chuo-Ku
2025-04-24
Recruiting
AbbVie
Phase 1
232
Kashiwa-shi, Hirakata-shi, Chuo-Ku
2025-04-14
Recruiting
AstraZeneca
Phase 3
600
Akashi-shi, Ginowan-shi, Hidaka-shi, Isehara-shi, Kashiwa, Kashiwa-shi, Kobe, Kōtoku
2025-03-27
Recruiting
Daiichi Sankyo
Phase 3
726
Bunkyō City, Chūōku, Gifu, Hiroshima, Kashiwa-shi, Kitakyushu, Kochi, Kōtoku
2025-02-27
Recruiting
AbbVie
Phase 2
150
Nagoya, Kashiwa-shi, Sapporo, Kobe, Sagamihara-shi, Sendai, Miyazaki, Kurashiki-shi
2025-01-20
Active, closed
AbbVie
Phase 1
21
Nagoya, Kashiwa-shi, Koto-ku
2025-01-16
Active, closed
Amgen
Phase 2
61
Nagoya, Kashiwa-shi, Sunto-gun, Chuo-ku, Koto-ku, Wakayama
2024-12-26
Active, closed
AbbVie
Phase 2
185
Nagoya, Kashiwa-shi, Sunto-gun, Chuo-Ku, Koto-ku
2024-12-13
Active, closed
Arcus Biosciences, Inc.
Phase 3
610
Kashiwa-shi, Kōtō City, Osaka, Tokyo, Toyama, Ube, Yokohama
2024-12-13
Active, closed
Amgen
Phase 3
707
Nagoya, Kashiwa-shi, Matsuyama, Maebashi, Sapporo, Kanazawa, Sagamihara-shi, Yokohama
2024-12-09
Active, closed
AbbVie
Phase 2
74
Nagoya, Kashiwa-shi, Suita-shi, Kitaadachi-gun, Chuo-Ku
2024-11-08
Active, closed
A Study of ZW191 in Participants With Solid Tumors
NCT06555744Advanced Solid Tumors
Zymeworks BC Inc.
Phase 1
145
Kashiwa-shi, Saitama, Tokyo
2024-10-30
Active, closed
Amgen
Phase 1
49
Nagoya, Kashiwa-shi, Sunto-gun, Wakayama
2024-09-17
Active, closed
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197Moderate to Severe Crohn's Disease
DrugAZD7798
AstraZeneca
Phase 2
120
Hiroshima, Kashiwa-shi, Kure-shi, Minatoku, Nagasaki, Nagoya, Sakura-shi, Sapporo
2024-08-28
Recruiting
Sumitomo Pharma America, Inc.
Phase 1/2
120
Kashiwa-shi, Kyoto
2024-08-14
Active, closed
AbbVie
Phase 3
111
Kashiwa-shi, Kurume-shi, Sendai, Izumi-Shi, Saga, Saitama-shi, Bunkyo-ku, Fuchu-shi
2024-08-08
Active, closed
EMD Serono Research & Development Institute, Inc.
Phase 1
60
Fukuoka, Kashiwa-shi, Kōtoku, Kumamoto
2024-08-07
Recruiting
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Phase 2
385
Asahikawa, Bunkyō, Chikushino-shi, Kashiwa-shi, Kobe, Kofu, Nagasaki, Nara
2024-07-18
Recruiting
Amgen
Phase 3
450
Nagoya, Chiba, Kashiwa-shi, Matsuyama, Fukuoka, Sapporo, Akashi-shi, Kawasaki-shi
2024-07-17
Recruiting
Guangzhou Virotech Pharmaceutical Co., Ltd.
Phase 1
12
Kashiwa-shi, Matsuyama, Kawasaki-shi
2024-07-10
Active, closed
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
464
Kashiwa-shi, Matsuyama, Gifu, Ota-Shi, Kure, Sapporo, Fukuoka, Akashi
2024-06-30
Recruiting
Boehringer Ingelheim
Phase 1/2
768
Aichi, Nagoya, Isehara, Kagoshima, Kanagawa, Yokohama, Kashiwa-shi, Kyoto, Osaka, Tokyo, Koto-ku
2024-06-28
Active, closed
Amgen
Phase 3
563
Nagoya, Kashiwa-shi, Matsuyama, Fukuoka, Kurume-shi, Sapporo, Akashi-shi, Yokohama
2024-06-05
Active, closed
Amgen
Phase 1
120
Nagoya, Kashiwa-shi, Yokohama, Chuo-ku
2024-05-29
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
31
Kashiwa-shi, Sendai, Niigata, Osaka, Osakasayama-shi, Sunto-gun, Chuo-ku, Koto-ku
2024-05-07
Active, closed
AbbVie
Phase 2/3
167
Kashiwa-shi, Kitaadachi-gun, Chuo-ku
2024-04-10
Active, closed
AbbVie
Phase 2
156
Gamagori-shi, Nagakute, Kashiwa-shi, Urayasu-shi, Kitakyushu-shi, Fukushima, Gifu, Ogaki-shi
2024-03-23
Recruiting
Eli Lilly and Company
Phase 3
90
Bunkyō City, Hirosaki, Kagoshima, Kashiwa-shi, Kobe, Saga, Sendai, Setagaya-ku
2024-03-13
Recruiting
Janssen Research & Development, LLC
Phase 3
120
Hirosaki, Kagoshima, Kashiwa-shi, Kobe, Saga, Sendai, Setagaya Ku, Tokyo
2024-03-13
Active, closed
AbbVie
Phase 1
152
Kashiwa-shi, Kyoto, Chuo-ku
2024-03-08
Recruiting
Daiichi Sankyo
Phase 2/3
860
Akashi-shi, Chūōku, Fukuoka, Hidaka-shi, Kashiwa-shi, Kōtoku, Minatoku, Nagaizumi-cho
2024-02-27
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
740
Hidaka, Kanagawa, Kashiwa-shi, Matsuyama, Nagaizumi-cho, Nagoya, Osakasayama-shi, Saitama
2024-02-26
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
762
Nagoya, Kashiwa-shi, Matsuyama, Kurume, Ota-Shi, Kobe, Kanazawa, Yokohama
2024-02-21
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
Nagoya, Kashiwa-shi, Matsuyama, Kurume-shi, Sapporo, Yokohama, Sendai, Niigata
2024-02-20
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 2
226
Nagoya, Kashiwa-shi, Matsuyama, Fukuoka, Yahatanishi-ku, Kitakyusyu-shi, Ota-shi, Hiroshima, Akashi-shi
2024-01-10
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Nagoya, Kashiwa-shi, Kurume, Kanazawa, Yokohama, Kyoto, Sendai, Ōsaka-sayama
2023-12-20
Recruiting
AbbVie
Phase 3
110
Ōbu, Kashiwa-shi, Kurume-shi, Maebashi, Kumamoto, Izumi-Shi, Saitama-shi, Bunkyo-ku
2023-12-11
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
87
Nagoya, Kashiwa-shi, Kanazawa, Yokohama, Osaka, Hamamatsu, Bunkyo-ku, Koto-Ku
2023-12-06
Recruiting
Amgen
Phase 3
750
Nagoya, Hirosaki-shi, Chiba, Kashiwa-shi, Matsuyama, Toon-shi, Fukuoka, Kitakyushu-shi
2023-11-16
Active, closed
AbbVie
Phase 3
289
Gamagori-shi, Kashiwa-shi, Nishinomiya-shi, Hamamatsu, Sunto-gun
2023-11-15
Active, closed
AbbVie
Phase 2
280
Nagoya, Kashiwa-shi, Kyoto, Sunto-gun, Chuo-ku
2023-11-12
Recruiting
AbbVie
Phase 1
325
Nagoya, Kashiwa-shi, Kyoto, Sunto-gun, Chuo-Ku, Koto-ku
2023-11-09
Active, closed
AbbVie
Phase 3
122
Kashiwa-shi, Kurume-shi, Sapporo, Sendai, Izumi-Shi, Osaka, Saitama-shi, Bunkyo-ku
2023-11-06
Active, closed
A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL
NCT06547528Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
DrugONO-4685
Ono Pharmaceutical Co., Ltd.
Phase 1
108
Nagoya, Akita, Kashiwa-shi, Fukuoka, Sapporo, Isehara-shi, Kumamoto, Kyoto
2023-10-01
Active, closed
AbbVie
Phase 2
130
Chiba, Kashiwa-shi, Kanazawa, Yokohama, Osakasayama-shi
2023-09-21
Recruiting
Regeneron Pharmaceuticals
Phase 3
410
Nagakute, Chiba, Kamogawa, Kashiwa-shi, Kurume, Ōgaki, Maebashi, Shibukawa
2023-09-18
Recruiting
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
DrugZipalertinib
Taiho Oncology, Inc.
Phase 2
220
Nagoya, Kashiwa-shi, Fukuoka, Sendai, Niigata, Sayama, Sunto-gun, Chuo Ku
2023-07-31
Recruiting
AbbVie
Observational
240
Anjo-shi, Handa, Nagakute, Nagoya, Toyohashi, Toyota-shi, Hachinohe, Kashiwa-shi
2023-07-28
Recruiting
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
NCT05727176Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
DrugFutibatinib
Taiho Oncology, Inc.
Phase 2
120
Sendai, Kashiwa-Shi, Nagasaki, Nagoya, Osaka-Fu
2023-07-05
Active, closed
AbbVie
Phase 1
135
Kashiwa-shi, Kyoto, Chuo-ku, Koto-ku
2023-06-09
Recruiting
Hoffmann-La Roche
Phase 3
100
Chiba, Fukuoka, Kanagawa, Kashiwa-shi, Saitama, Sakaishi
2023-06-01
Active, closed
Amgen
Phase 3
509
Nagoya, Kashiwa-shi, Matsuyama, Kurume-shi, Sapporo, Akashi-shi, Yokohama, Sendai
2023-05-31
Recruiting
Chugai Pharmaceutical
Phase 1
209
Nagoya, Kashiwa-shi, Yokohama, Hirakata-shi, Osaka, Sakai-shi, Nagaizumi-chō, Chuo-ku
2023-05-24
Active, closed
Genmab
Phase 3
900
Nagoya, Kashiwa-shi, Matsuyama, Fukuoka, Fukushima, Sapporo, Kobe, Tsukuba
2023-02-08
Active, closed
A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
NCT05658562Diffuse Large B-Cell Lymphoma
Tanabe Pharma Corporation
Phase 1/2
46
Nagoya, Kashiwa-shi, Fukuoka, Iizuka-shi, Fukushima, Gifu, Ota-shi, Sapporo
2023-01-30
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
DrugObefazimod
Abivax S.A.
Phase 3
1,116
Toyohashi, Kashiwa-shi, Matsuyama, Chikushino-shi, Iizuka-shi, Kurume-shi, Ota-shi, Fukuyama-shi
2023-01-16
Active, closed
AbbVie
Phase 1
288
Kashiwa-shi, Matsuyama, Sapporo, Kyoto, Sunto-gun, Chuo-ku, Koto-ku, Wakayama
2022-12-05
Recruiting
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
Chiba, Kashiwa-shi, Matsuyama, Fukuoka, Sapporo, Kobe, Kita-gun, Kawasaki-shi
2022-10-24
Active, closed
AbbVie
Phase 1
283
Nagoya, Kashiwa-shi, Sapporo, Kanazawa, Okayama, Yamagata
2022-10-20
Active, closed
Genmab
Phase 3
549
Nagoya, Toyoake, Kashiwa-shi, Matsuyama, Fukuoka, Fukushima, Sapporo, Kobe
2022-09-20
Active, closed
Amgen
Phase 1
184
Kashiwa-shi, Koto-ku
2022-08-24
Active, closed
EMD Serono Research & Development Institute, Inc.
Phase 1
220
Chūōku, Kashiwa-shi, Kitaadachi-gun, Kōtoku, Nagoya, Osakasayama-shi, Sunto-gun, Yokohama
2022-08-04
Recruiting
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
372
Kashiwa-shi, Sapporo, Suita-shi, Tokushima, Koto-ku, Osaka
2022-05-03
Recruiting
AbbVie
Phase 3
768
Nagoya, Hirosaki-shi, Kashiwa-shi, Fukuoka, Kitakyushu-shi, Kurume-shi, Ota-shi, Fukuyama
2022-03-25
Active, closed
AbbVie
Phase 1
8
Kashiwa-shi, Sapporo, Kanazawa, Okayama, Suita-shi, Yamagata
2022-03-24
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
Kamogawa, Kashiwa-Shi, Matsuyama, Fukuoka, Fukushima, Sapporo, Tsukuba, Kanazawa
2022-03-07
Active, closed
Daiichi Sankyo
Phase 3
740
Aomori, Kashiwa-shi, Matsuyama, Fukuoka, Kurume-shi, Kanazawa, Yokohama, Kumamoto
2022-03-04
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
DrugsAzoles·Gilteritinib·Azacitidine·Venetoclax
Sumitomo Pharma America, Inc.
Phase 1/2
606
Kashiwa-shi, Yoshida-gun, Fukushima, Isehara-shi, Nagasaki, Bunkyo-ku, Bunkyō City, Fukuoka
2022-02-28
Active, closed
Amgen
Phase 1/2
329
Nagoya, Kashiwa-shi, Chuo-ku
2022-02-01
Active, closed
Bristol-Myers Squibb
Phase 2
19
Nagoya, Toyoake, Aomori, Kamogawa, Kashiwa-shi, Matsuyama, Yoshida Gun, Fukuoka
2022-01-17
Active, closed
Jazz Pharmaceuticals
Phase 3
920
Chiba, Kashiwa-shi, Gifu, Ota-shi, Akashi-shi, Kasama-Shi, Kita-Gun Miki-Cho, Yokohama-Shi Asahi-Ku
2021-12-02
Active, closed
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
NCT05060016Relapsed/Refractory Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 2
222
Nagoya, Kashiwa-shi, Okayama, Osakasayama-shi, Sunto-gun, Koto-ku, Wakayama
2021-12-01
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 3
626
Kashiwa-shi, Yokohama, Osaki-shi, Suita-shi, Hidaka-shi, Ina-machi, Kitaadati-gun, Nagaizumi-Cho, Sunto-Gun, Bunkyo-ku
2021-11-05
Recruiting
AbbVie
Phase 1
694
Nagoya, Kashiwa-shi, Kobe, Hirakata-shi, Sunto-gun, Chuo-ku, Wakayama
2021-11-01
Active, closed
AbbVie
Phase 1
520
Nagoya, Kashiwa-shi, Yokohama, Kyoto, Niigata, Chuo-ku, Koto-ku, Wakayama
2021-10-13
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
32
Kashiwa-shi, Yokohama, Hamamatsu, Bunkyō-Ku, Koto-ku, Mitaka-shi, Shinjuku-Ku, Chūōku
2021-07-30
Active, closed
Incyte Corporation
Phase 3
654
Fukuoka, Fukuyama-shi, Gifu, Kagoshima, Kashiwa-shi, Kitakyushu-shi, Kobe, Nagoya
2021-04-15
Active, closed
AbbVie
Phase 1
81
Nagoya, Kashiwa-shi, Matsuyama, Fukuoka, Chuo-ku
2021-02-23
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
40
Kashiwa-shi, Kobe, Yokohama, Ina, Osaka, Takatsuki-shi, Hidaka-shi, Koto-Ku
2021-01-13
Active, closed
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
NCT04579380Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms
DrugsTucatinib·Herceptin·Fulvestrant·Trastuzumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
217
Nagoya, Kashiwa-shi, Kawasaki, Osakasayama-shi, Cho-ku, Tokyo
2021-01-11
Active, closed
Amgen
Phase 1/2
181
Akita, Kashiwa-shi, Fukushima, Yokohama, Yokohami-shi
2021-01-04
Active, closed
Daiichi Sankyo
Phase 1
179
Chuo Ku, Kashiwa-shi, Fukuoka, Kōtoku, Matsuyama, Nakatogari, Saitama
2020-12-22
Recruiting
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
NCT04683250RET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors
Taiho Pharmaceutical Co., Ltd.
Phase 1/2
244
Kashiwa-shi, Sendai, Okayama, Hirakata-shi, Osaka, Shizuoka, Chuo-ku, Koto-ku
2020-12-16
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
281
Fukushima, Kanazawa, Kashiwa-shi, Kita-ku, Kumamoto, Matsumoto-shi, Nagoya, Shibuya-ku
2020-11-03
Active, closed
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
NCT04452591Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
DrugCretostimogene Grenadenorepvec
CG Oncology, Inc.
Phase 3
190
Kashiwa-shi, Tōon, Sapporo, Kandori, Marugame, Kawasaki, Yokohama, Kyoto
2020-10-27
Active, closed
Exelixis
Phase 3
575
Toyota-shi, Akita, Hirosaki, Kashiwa-shi, Sakura-shi, Sapporo, Kobe, Kita-gun
2020-10-19
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
40
Nagoya, Kashiwa-shi, Kawasaki, Osaka, Chuo-ku, Koto-ku
2020-09-15
Active, closed
AbbVie
Phase 3
330
Nagoya, Toyoake, Aomori, Chiba, Kashiwa-shi, Toon-shi, Fukuoka, Fukushima
2020-08-31
Active, closed
AstraZeneca
Phase 3
805
Chūōku, Kashiwa-shi, Kōtoku, Kurume-shi, Kyoto, Matsuyama, Minatoku, Nagoya
2020-05-05
Recruiting
Amgen
Phase 1
479
Kashiwa-shi, Yokohama, Koto-ku
2020-03-04
Active, closed
Takeda
Phase 3
354
Toyoake-Shi, Kashiwa-Shi, Matsuyama, Sapporo, Kurume-Shi, Yokohama, Kumamoto, Natori-shi
2020-01-10
Active, closed
EMD Serono Research & Development Institute, Inc.
Phase 1
161
Chūōku, Kashiwa-shi
2019-12-20
Active, closed
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT04185883Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
DrugsBI 1701963·TNO155·Sotorasib·Afatinib
Amgen
Phase 1
610
Nagoya, Kashiwa-shi, Koto-ku
2019-12-17
Active, closed
Regeneron Pharmaceuticals
Phase 2
515
Nagoya, Chiba, Kashiwa-shi, Matsuyama, Fukuoka, Kobe, Isehara-Shi, Kyoto
2019-11-13
Active, closed
Bristol-Myers Squibb
Phase 3
461
Nagoya, Kashiwa-shi, Kitakyushu-shi, Hiroshima, Kobe, Kanazawa, Yokohama, Sendai
2019-11-05
Active, closed
Pfizer
Phase 3
896
Nagoya, Toyohashi, Kashiwa-shi, Nagareyama-shi, Sakura, Fukuoka, Kasuga, Kasuga-shi
2019-09-05
Recruiting
Bristol-Myers Squibb
Phase 2
1,500
Hirosaki-shi, Chiba, Kashiwa-Shi, Matsuyama, Fukuoka, Kobe, Tsukuba, Kanazawa
2019-08-09
Active, closed
Bristol-Myers Squibb
Phase 3
839
Nagoya, Chiba, Kashiwa-shi, Matsuyama, Fukuoka, Sapporo, Kanazawa, Kawasaki
2019-08-05
Active, closed
AbbVie
Phase 1
364
Kashiwa-shi, Akashi-shi, Chuo-ku
2019-02-21
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
387
Nagoya, Kashiwa-shi, Maebashi, Kasama-shi, Kyoto, Hidaka, Tokushima, Shibuya-ku
2019-01-23
Active, closed
AstraZeneca
Phase 3
1,407
Fukuoka, Kashiwa-shi, Kobe, Kōtoku, Kurume-shi, Kyoto, Minatoku, Nagoya
2019-01-04
Active, closed
AbbVie
Phase 3
265
Nagoya, Kashiwa-shi, Fukuoka, Ogaki-shi, Maebashi, Hiroshima, Kobe, Higashi Ibaraki-gun
2018-10-22
Active, closed
AbbVie
Phase 3
1,242
Nagakute, Nagoya, Toyoake, Hirosaki-shi, Abiko-shi, Chiba, Kashiwa-shi, Sakura-shi
2018-08-28
Active, closed
Bristol-Myers Squibb
Phase 3
545
Kashiwa-shi, Kurume-shi, Sapporo, Nishinomiya-shi, Morioka, Kumamoto, Osaka, Ōsaka-sayama
2018-04-18
Active, closed
AbbVie
Phase 3
1,336
Nagakute, Nagoya, Toyoake-shi, Abiko-shi, Chiba, Kashiwa-shi, Sakura-shi, Fukuoka
2018-04-09
Active, closed
Amgen
Phase 1
269
Kashiwa-shi, Chuo-ku, Wakayama
2017-12-26
Active, closed
Daiichi Sankyo
Phase 1
312
Kashiwa-Shi, Kurume-Shi, Osaka, Shizuoka, Tokyo
2017-10-30
Active, closed
ModernaTX, Inc.
Phase 1
161
Kashiwa-Shi, Chuo-Ku, Tokyo, Osakasayama-Shi
2017-08-14
Active, closed
AbbVie
Phase 1
163
Kashiwa-shi, Chuo-ku
2017-02-22
Active, closed
AbbVie
Phase 3
950
Nagakute, Nagoya, Toyohashi, Toyota-shi, Hirosaki-shi, Abiko-shi, Kashiwa-shi, Sakura-shi
2017-01-31
Active, closed
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
NCT02864992Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
DrugTepotinib
EMD Serono Research & Development Institute, Inc.
Phase 2
337
Fukuoka, Kashiwa-shi, Kitaadachi-gun, Kurume-shi, Matsuyama, Nagoya, Niigata, Osaka
2016-09-13
Active, closed
AbbVie
Phase 1
237
Kashiwa-shi, Chuo-ku
2014-01-15
Recruiting
Phase III Trial of Stage I Ovarian Cancer After Surgery
NCT04063527Epithelial Ovarian Cancer
Japanese Gynecologic Oncology Group
Phase 3
360
Nagakute-shi, Seto-shi, Toyoake-shi, Hirosaki-shi, Kashiwa-shi, Onsen-gun, Fukuoka, Kurume-shi
2012-07-20
Rows per page Showing 1–137 of 137
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/kashiwa-shi

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 137 of those studies with a site in Kashiwa-shi.

How many clinical trials are recruiting in Kashiwa-shi?

58 of the 137 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 79 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Kashiwa-shi), 137 studies
PhaseStudiesRecruitingShare
Phase 3542139.4%
Phase 1401229.2%
Phase 2271319.7%
Phase 1/21077.3%
Observational442.9%
Phase 2/3211.5%

Most active sponsors

Lead sponsors with the most studies (Kashiwa-shi)
Lead sponsorStudiesRecruiting
AbbVie4217
Amgen185
AstraZeneca85
Daiichi Sankyo85
Ono Pharmaceutical Co., Ltd.70
Bristol-Myers Squibb62
Seagen, a wholly owned subsidiary of Pfizer62
EMD Serono Research & Development Institute, Inc.40
Incyte Corporation32
Regeneron Pharmaceuticals32
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.